PARLIAMENTARY WRITTEN QUESTION
Liver Diseases: Screening (5 January 2024)

FibroScan capacity is being increased across England via the Community Diagnostics Centre (CDC) programme, backed as part of a £2.3 billion investment in diagnostic transformation. The National Health Service currently plans for 11 sites to be live with FibroScans by the end of this financial year, with seven presently live with the test. By March 2025 we expect there to be 15 CDCs offering FibroScans.

The CDC test offer is based on the recommendations in the Sir Mike Richards Review, and decisions on what modalities are offered outside of the core requirements of CDCs, including FibroScans, will be based on local need as well as local funding decisions and considerations.

Through the £2.3 billion diagnostics transformation programme, NHS England is ensuring that laboratories across the country have the digital capability required to offer Intelligent Liver Function Tests.

The NHS is also delivering and considering the result from the pilot of the community liver health check programme, which is due to deliver 22,000 FibroScans per year to communities at particular risk of liver disease. From June 2022 to September 2023, over 26,500 FibroScans were delivered through the pilots, and 8% of people scanned have already been enrolled into liver surveillance programmes. The programme is being delivered across 19 areas by Hepatitis C Operational Delivery Networks to FibroScan patients at high risk of cirrhosis or advanced fibrosis, utilising 40 FibroScan machines.

NHS England is reviewing existing liver diagnosis pathways as part of its wider diagnostic transformation work, to determine what the best approach should be to identify patients at an earlier stage of liver disease, through a liver pathway starting in primary care and involving pathology labs and CDCs. This will include a combination of blood tests and FibroScans.